Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells

Toxicology and Applied Pharmacology

Volumn 239, Issue 1, 2009, Pages 64-70

  Charoensuk, Vichaya ^a   Gati, Wendy P ^a   Weinfeld, Michael ^a   Le, X Chris ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Apoptosis; Arsenate; Arsenic trioxide; Autophagic cell death; Autophagy; Dimethylarsinic acid; Flow cytometry; Monomethylarsonic acid; Monomethylarsonous acid; Phenlyarsine oxide

Indexed keywords

ARSENATE SODIUM; ARSENIC DERIVATIVE; ARSENIC TRIOXIDE; ARSENOSOBENZENE; CACODYLIC ACID; CASPASE 3; METHANEARSONIC ACID; METHANEARSONOUS ACID; MICROTUBULE ASSOCIATED PROTEIN 1; MICROTUBULE ASSOCIATED PROTEIN 1 LIGHT CHAIN 3; PHOSPHATIDYLSERINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; PROMYELOCYTIC LEUKEMIA;

APOPTOSIS; ARSENICALS; AUTOPHAGY; CASPASE 3; CELL SURVIVAL; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; MICROTUBULE-ASSOCIATED PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67650684946     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.05.016     Document Type: Article

References (51)

1. Akao Y., Nakagawa Y., and Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett. 455 (1999) 59-62
2. Antman K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6 (2001) 1-2
3. ATSDR, Agency for Toxic Substances and Disease Registry, 2000. Toxicological profile for Arsenic (update). U.S. Public Health Services, Atlanta, GA.
4. Au W.Y., Lie A.K.W., Chim C.S., Liang R., Ma S.K., Chan C.H., Mak Y.K., Chen Y.T., So C.C., Yeung Y.M., Yip S.F., Wong L.G., Chan J.C., Liu S.Y., and Kwong Y.L. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann. Oncol. 14 (2003) 752-757
5. Bae O.N., Lim K.M., Noh J.Y., Chung S.M., Kim S.H., and Chung J.H. Trivalent methylated arsenical-induced phosphatidylserine exposure and apoptosis in platelets may lead to increased thrombus formation. Toxicol. Appl. Pharmacol. (2009) [Jan 6., Electronic publication ahead of print]
6. Bursch W., Ellinger A., Gerner C., Frohwein U., and Schulte-Hermann R. Programmed cell death (PCD) - apoptosis, autophagic PCD, or others?. Ann. N. Y. Acad. Sci. 926 (2000) 1-12
7. Chai C.Y., Huang Y.C., Hung W.C., Kang W.Y., and Chen W.T. Arsenic salts induced autophagic cell death and hypermethylation of DAPK promoter in SV-40 immortalized human uroepithelial cells. Toxicol. Lett. 173 (2007) 48-56
8. 3 exerts dose-dependent dual effects on APL cells. Blood 89 (1997) 3345-3353
9. Chen G.Q., Zhou L., Styblo M., Walton F., Jing Y.K., Weinberg R., and Waxman S. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 63 (2003) 1853-1859
10. Cheng T.J., Wang Y.J., Kao W.W., Chen R.J., and Ho Y.S. Protection against arsenic trioxide-induced autophagic cell death in U118 human glioma cells by use of lipoic acid. Food Chem. Toxicol. 45 (2007) 1027-1038
11. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 326 (1997) 1-16
12. Davis M. Introduction. In: Davis M. (Ed). Apoptosis Methods in Pharmacology and Toxicology (2002), Humana Press, New Jersey
13. Dilda P.J., and Hogg P.J. Arsenical-based cancer drugs. Cancer Treat. Rev. 33 (2007) 542-564
14. Estrov Z., Manna S.K., Harris D., Van Q., Estey E.H., Kantarjian H.M., Talpaz M., and Aggarwal B.B. Phenylarsine oxide blocks interleukin-1 beta-induced activation of the nuclear transcription factor NF-kappa B, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 94 (1999) 2844-2853
15. Fink S.L., and Cookson B.T. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect. Immun. 73 (2005) 1907 1916
16. Gati, W.P., (2007). Flow cytometry. In Handbook of Neurochemistry and Molecular Neurobiology (Lajtha, A., Ed.), 3rd Edition, Volume 18 (Practical Neurochemistry Methods; Baker, G., Dunn, S., Holt, A., Eds.). chapter 13, pp. 305-321. Springer, New York.
17. Gupta S., Yel L., Kim D., Kim C., Chiplunkar S., and Gollapudi S. Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. Mol. Cancer Ther. 2 (2003) 711-719
18. Han Y.H., Kim S.Z., Kim S.H., and Park W.H. Arsenic trioxide inhibits growth of As4.1 juxtaglomerular cells via cell cycle arrest and caspase-independent apoptosis. Am. J. Physiol. Renal Physiol. 293 (2007) F511-F520
19. Herault O., Colombat P., Domenech J., Degenne M., Bremond J.L., Sensebe L., Bernard M.C., and Binet C. A rapid single-laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population. Br. J. Haematol. 104 (1999) 530-537
20. Hirano S., Kobayashi Y., Cui X., Kanno S., Hayakawa T., and Shraim A. The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol. Appl. Pharmacol. 198 (2004) 458-467
21. Kanzawa T., Kondo Y., Ito H., Kondo S., and Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 63 (2003) 2103-2108
22. Kanzawa T., Germano I.M., Komata T., Ito H., Kondo Y., and Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11 (2004) 448-457
23. Kanzawa T., Zhang L., Xiao L.C., Germano I.M., Kondo Y., and Kondo S. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 24 (2005) 980-991
24. Kitamura K., Minami Y., Yamamoto K., Akao Y., Kiyoi H., Saito H., and Naoe T. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 14 (2000) 1743-1750
25. Kitchin K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172 (2001) 249-261
26. Korge P., Goldhaber J.I., and Weiss J.N. Phenylarsine oxide induces mitochondrial permeability transition, hypercontracture, and cardiac cell death. Am. J. Physiol, Heart Circ. Physiol. 280 (2001) H2203-H2213
27. Kroemer G., El-Deiry W., Golstein P., Peter M.E., Vaux D., Vandenabeele P., Zhivotovsky B., Blagosklonny M.V., Malorni W., Knight R.A., Piacentini M., Nagata S., and Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 12 (2005) 1463-1467
28. Larochette N., Decaudin D., Jacotot E., Brenner C., Marzo I., Susin S.A., Zamzami N., Xie Z.H., Reed J., and Kroemer G. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp. Cell Res. 249 (1999) 413-421
29. 3) in the treatment of patients with acute promyelocytic leukemia - the M. D. Anderson experience. Cancer 97 (2003) 2218-2224
30. Li X.Q., Ding X.Z., and Adrian T.E. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas 27 (2003) 174-179
31. McCafferty-Grad J., Bahlis N.J., Krett N., Aguilar T.M., Reis I., Lee K.P., and Boise L.H. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol. Cancer Ther. 2 (2003) 1155-1164
32. Megyesi J.F., Findlay J.M., Vollrath B., Cook D.A., and Chen M.H. In vivo angioplasty prevents the development of vasospasm in canine carotid arteries - pharmacological and morphological analyses. Stroke 28 (1997) 1216-1224
33. Miller W.H., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 62 (2002) 3893-3903
34. Park J.W., Choi Y.J., Jang M.A., Baek S.H., Lim J.H., Passaniti T., and Kwon T.K. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and Bcl-2 phosphorylation in promonocytic U937 cells. Biochem. Biophys. Res. Commun. 286 (2001) 726-734
35. Petrick J.S., Ayala-Fierro F., Cullen W.R., Carter D.E., and Aposhian H.V. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 163 (2000) 203-207
36. Pu Y.S., Hour T.C., Chen J., Huang C.Y., Guan J.Y., and Lu S.H. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma - characterizing its apoptotic pathway. Anti-Cancer Drug 13 (2002) 293-300
37. Qian W.B., Liu J.Q., Jin J., Ni W.M., and Xu W.L. Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leuk. Res. 31 (2007) 329-339
38. 3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br. J. Haematol. 116 (2002) 555-563
39. Rousselot P., Labaume S., Marolleau J.P., Larghero J., Noguera M.H., Brouet J.C., and Fermand J.P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 59 (1999) 1041-1048
40. 3 by activating the mitochondrial pathway. Leuk. Lymp. 45 (2004) 987-995
41. Sakurai T., Ochiai M., Kojima C., Ohta T., Sakurai M.H., Takada N.O., Qu W., Waalkes M.P., and Fujiwara K. Role of glutathione in dimethylarsinic acid-induced apoptosis. Toxicol. Appl. Pharmacol. 198 (2004) 354-365
42. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., Stone R.M., Kalaycio M., Scheinberg D.A., Steinherz P., Sievers E.L., Coutre S., Dahlberg S., Ellison R., and Warrell R.P. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19 (2001) 3852-3860
43. Styblo M., Del Razo L.M., Vega L., Germolec D.R., LeCluyse E.L., Hamilton G.A., Reed W., Wang C., Cullen W.R., and Thomas D.J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 74 (2000) 289-299
44. Tanida I., Minematsu-Ikeguchi N., Ueno T., and Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 1 (2005) 84-91
45. Thomas D.J., Li J., Waters S.B., Xing W., Adair B.M., Drobna Z., Devesa V., and Styblo M. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp. Biol. Med. 232 (2007) 3-13
46. Van Cruchten S., and Van Den Broeck W. Morphological biochemical aspects of apoptosis, oncosis and necrosis. Anat. Histol. Embryol. 31 (2002) 214-223
47. Walter R., Schoedon G., Bachli E., Betts D.R., Hossle J.P., Calandra T., Joller-Jemelka H.I., Fehr J., and Schaffner A. Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). Br. J. Haematol. 109 (2000) 396-404
48. Watson R.W.G., Redmond H.P., Wang J.H., and Bouchier-Hayes D. Mechanisms involved in sodium arsenite-induced apoptosis of human neutrophils. J. Leukoc. Biol. 60 (1996) 625-632
49. Waxman S., and Anderson K.C. History of the development of arsenic derivatives in cancer therapy. Oncologist 6 (2001) 3-10
50. Yang Y.P., Liang Z.Q., Gao B., Jia Y.L., and Qin Z.H. Dynamic effects of autophagy on arsenic trioxide-induced death of human leukemia cell line HL60 cells. Acta Pharmacol. Sin. 29 (2008) 123-134
51. Zhou X., Yoshida K., Kuroda K., Endo Y., and Endo G. Effects of cysteine on the cytotoxicity of arsenic compounds. Arch. Environ. Contam. Toxicol. 45 (2003) 324-330